{"organizations": [], "uuid": "b56d70f4a69af7198ee45b916c74a40be8766b3f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/10/21/biogen-restructuring-idUSL3N12L3WX20151021", "country": "US", "title": "UPDATE 1-Biogen to cut 11 pct of workforce", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "UPDATE 1-Biogen to cut 11 pct of workforce | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-10-21T16:08:00.000+03:00", "replies_count": 0, "uuid": "b56d70f4a69af7198ee45b916c74a40be8766b3f"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/10/21/biogen-restructuring-idUSL3N12L3WX20151021", "ord_in_thread": 0, "title": "UPDATE 1-Biogen to cut 11 pct of workforce", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds details; shares)\nOct 21 (Reuters) - Biogen Inc said it would cut 11 pct of its global workforce by the end of this year and stop a late-stage study on its blockbuster drug Tecfidera for secondary progressive MS, sending its shares up 7 percent in premarket trading.\nBiogen, which had about 7,550 employees as of Dec. 31, said it expects to incur charges of $85 million-$95 million, primarily in the fourth quarter.\nTecfidera is already approved for the treatment of multiple sclerosis.\nBiogen has also discontinued several other development programs, including a drug for lupus nephritis.\nThe company, which has five FDA-approved MS drugs, said net profit attributable to Biogen rose to $965.6 million, or $4.15 per share, in the third quarter ended Sept. 30, from $856.8 million, or $3.62 per share, a year earlier.\nRevenue rose 11 percent to $2.8 billion, driven by higher demand for Tecfidera. (Reporting by Rosmi Shaji in Bengaluru; Editing by Don Sebastian)", "external_links": [], "published": "2015-10-21T16:08:00.000+03:00", "crawled": "2015-10-21T15:19:24.109+03:00", "highlightTitle": ""}